Piper Sandler analyst Jason Bednar downgraded Pulmonx (LUNG) to Neutral from Overweight with a price target of $2.50, down from $9, following the Q2 report. The company posted its sixth consecutive quarter of decollation in the high-margin U.S. business. Piper no longer has confidence in management’s updated full-year outlook or that Pulmonx can return to 15%-20% sales growth.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG: